Clinical Report: Weekly Administration of Semaglutide in Adult Smokers

Overview

This phase 2a randomized clinical trial evaluated the effects of semaglutide monotherapy on smoking-related outcomes in adults who smoke but are not seeking cessation. While semaglutide did not significantly reduce the number of cigarettes smoked per day, it was associated with greater reductions in nicotine craving and body weight compared to placebo.

Background

Cigarette smoking is a leading cause of preventable morbidity and mortality, contributing to numerous health issues including cardiovascular diseases and type 2 diabetes. Current smoking cessation therapies are limited, necessitating the exploration of new treatments that can address both cessation and associated health risks. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide have shown promise in improving cardiometabolic outcomes and may offer a novel approach to smoking cessation.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• Semaglutide monotherapy did not significantly reduce the number of cigarettes smoked per day.
• Participants receiving semaglutide experienced greater reductions in nicotine craving compared to those on placebo.
• Weight loss was observed in the semaglutide group, which may address concerns about postcessation weight gain.
• The trial included adults aged 21 to 65 who reported smoking at least 5 cigarettes per day.
• This study is the first to evaluate the effects of GLP-1RA monotherapy on smoking outcomes in non-cessation contexts.

Clinical Implications

The findings suggest that semaglutide may help reduce nicotine cravings and manage weight in smokers, which could be beneficial for those concerned about weight gain after cessation. However, its lack of impact on the number of cigarettes smoked indicates that further research is needed to fully understand its role in smoking cessation strategies.

Conclusion

While semaglutide shows potential in reducing cravings and managing weight among smokers, its efficacy in reducing cigarette consumption remains unproven. Continued investigation into GLP-1RAs for smoking cessation is warranted.

Related Resources & Content

1. Conexiant, Conexiant, 2023 -- Semaglutide Reduced Nicotine Craving in Small Trial
2. Open Forum Infectious Diseases, Open Forum Infectious Diseases, 2023 -- Impact of Semaglutide on Immune Activation and Inflammatory Markers in Individuals with HIV-related Lipohypertrophy
3. Conexiant, Conexiant, 2023 -- Semaglutide Tested in Alcohol Use Disorder
4. European Journal of Preventive Cardiology, European Journal of Preventive Cardiology, 2023 -- Impact of Smoking Cessation on Blood Pressure Variations in a Randomized, Double-Blind, Placebo-Controlled Study of Dulaglutide Therapy
5. CDC, CDC, 2024 -- Clinical Interventions to Treat Tobacco Use and Dependence Among Adults | Smoking and Tobacco Use
6. ScienceDirect, ScienceDirect, 2025 -- Efficacy and safety of varenicline for electronic cigarette cessation: A systematic review and meta-analysis
7. JAMA Network, JAMA Network, 2023 -- Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial
8. Clinical Interventions to Treat Tobacco Use and Dependence Among Adults | Smoking and Tobacco Use | CDC
9. Efficacy and safety of varenicline for electronic cigarette cessation: A systematic review and meta-analysis - ScienceDirect
10. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network